|

Baricitinib Clinical Trials

9 actively recruiting trials across 5 locations

Also known as: LY3009104, Olimuant, Olumiant, fluorodésoxyglucose (18F)- Positron Emission Tomography (PET)

Other3 trials

A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
Phase 2
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Phase 3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Phase 3

Atlanta, Georgia2 trials

Inflammation and Depression in People With HIV

Grady Memorial Hospital

Phase 2
JAK Signaling in Depression

Emory University

Phase 2

Anniston, Alabama1 trial

ConsideRAte Study - Splenic Stimulation for RA

Pinnacle Research Group, LLC

N/A

Tallahassee, Florida1 trial

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Tallahassee Memorial HealthCare

Phase 3

Bethesda, Maryland1 trial

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

National Institutes of Health Clinical Center

Phase 1

Omaha, Nebraska1 trial

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

University of Nebraska Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.